Should You Buy Galecto Inc (GLTO) Stock After it Has Gained 3.03% in a Week?

Galecto Inc (GLTO) stock has gained 3.03% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Galecto Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on GLTO!

See Full GLTO Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With GLTO Stock Today?

Galecto Inc (GLTO) stock has gained 8.43% while the S&P 500 is lower by -0.09% as of 3:58 PM on Friday, Jan 26. GLTO is up $0.05 from the previous closing price of $0.62 on volume of 544,027 shares. Over the past year the S&P 500 has gained 21.75% while GLTO is lower by -66.50%. GLTO lost -$1.76 per share in the over the last 12 months.

More About Galecto Inc

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis. Click Here to get the full Stock Report for Galecto Inc stock.